NYSE: RVTY

Revvity (RVTY) Stock Analysis & Forecast

Nov 13 close

$154.39−2.63 (−1.7%)

Gekko Brief

AI summaryNov 9 close

Revvity's shares advanced this week on strong third quarter results, with pro forma revenue rising 7% year-over-year to $710 million and statutory earnings per share beating forecasts by 13%, driven by the Life Sciences and Diagnostics segments. The results prompted a wave of analyst price target increases, including Barclays lifting its target to $175 from $160 while maintaining an Equal-Weight rating, and TD Cowen raising its target to $185 from $175 while reiterating a Buy rating. A separate rating upgrade to Buy was also noted, alongside commentary suggesting that while organic revenue and AI-driven demand remain strong, current valuations may already reflect expected improvement.

Revvity closed at $160.72, up 3.6%, sitting above both its 50-day average of $148.16 and its 200-day average of $113.14, with the 50-day above the 200-day. The GekkoIndex reads 55, placing the stock in the Neutral zone. Price stands 17.9% above Gekko Fair Value of $136.36, a gap that contrasts with the consensus target of $149.87 from 14 firms, six rating it Buy and eight Hold.

The next earnings report is scheduled for 1 February 2027, 78 days away, placing it outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality data shows the next 20 trading days have averaged a 4.3% gain over 5 years, rising in 4 of them, a pattern worth noting alongside the current gap to Gekko Fair Value.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Revvity price vs fair value

$154.39$141.76Nov ’25May ’26Nov ’26
Close $154.39200-day averageGekko Fair Value $141.76

Revvity quick facts

Market cap
$17.24B
P/E ratio
70.4
Forward P/E
26.4
EPS, TTM
$2.23
Revenue, TTM
$2.94B
Profit margin
8.6%
Dividend yield
0.18%
Beta
1.09
Volume
1.31M avg 1.84M
1-year return
+64.0%
Typical daily move
±5.6%
Typical 20-day move
±5.8%
50-day average
$150.40
200-day average
$114.03
Next earnings
Feb 1 before open
Shares outstanding
111.6M
52-week range
$81.22$171.74

Revvity swing-trade checklist

Revvity scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $154.39 is above the 50-day ($150.40) and 200-day ($114.03) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    59.7, Neutral

    Reading 59.7 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    8.9% above

    Price is 8.9% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 78 days

    Next report Feb 1, 2027, 78 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.8% on average

    From this point in the calendar, the next 20 trading days averaged +3.8% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Revvity stock chart and price history

Revvity closed at $154.39 on Nov 13, 2026, +64.0% over the past year, inside a 52-week range of $81.22 to $171.74.

Close50-day average200-day averageVolume
Revvity share price, past year, with 50-day and 200-day moving averages and volume$80$100$120$140$160DecJan 2026FebMarAprMayJunJulAugSepOctNov154.39

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−0.2%
3 months
+32.9%
6 months
+64.3%
1 year
+64.0%
The full RVTY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RVTY in Gekko

Follow Revvity through every session

Put RVTY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track RVTY in GekkoFree for 7 days. No credit card required.

About Revvity

Revvity supplies instruments, reagents, software and related services used in scientific research and health screening. The company works across life sciences and diagnostics, offering tools such as detection and imaging technology, laboratory instrumentation, and testing platforms used to identify genetic and infectious conditions. It is recognized for products that support screening for disorders such as Down syndrome and metabolic conditions, as well as tools used in genomic research.

The company operates through two main areas. One focuses on instruments, reagents, informatics and contract laboratory work for life sciences research, environmental testing, agriculture and food analysis, and industrial applications like chemicals, semiconductors and energy. The other centers on diagnostics, providing assay systems and sequencing-based tools used in prenatal and childhood screening, infectious disease testing, oncology and drug discovery. Its customers include pharmaceutical and biotechnology firms, laboratories, academic institutions, healthcare providers, public health agencies and government organizations.

Revvity's shares are listed on the NYSE under the ticker RVTY.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
revvity.com

Revvity GekkoIndex: the smart money zone

Revvity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.7, in the Neutral zone, up 2.8 points over five sessions.

010059.7Neutral

Up 2.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying19+1.8%+1.2%+2.8%+7.3%
Accumulation251+0.5%+0.9%+1.2%+2.2%
Neutral (current zone)388+0.4%+0.9%+2.0%+4.7%
Distribution43−1.2%−2.1%−2.1%−1.4%
Selling1Too few readings yet

Average RVTY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the RVTY price, zone by zone.Track RVTY in Gekko

Is Revvity stock overvalued? Gekko Fair Value

Revvity trades 8.9% above Gekko Fair Value of $141.76, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Revvity shares are worth, recalculated every trading day.

$141.76

Gekko Fair Value, Nov 14, 2026

8.9% Overvalued

At the end of Aug 2026 the price was 18.1% above the estimate.

Gekko Fair ValueShare price, month end
$142$154Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open RVTY in Gekko

Revvity insider and Congress trading

No open-market insider purchases were filed for Revvity, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for RVTY in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every RVTY insider filing, plotted on the chart in Gekko.Open RVTY in Gekko

Congress trades last 90 days

No trades in RVTY were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for RVTY, plotted on the chart in Gekko.Open RVTY in Gekko

Buybacks

Revvity has been buying back its own shares.

Bought back, quarter ended Oct 4, 2026
$95K
As a share of market cap
0.00%
Trailing four quarters
$270.9M

From company filings.

Unusual options activity last 30 days

1signal, 74% of the flagged premium in calls.

Latest: Bullish flow on Nov 11, $366K in unusual premium.

Every signal with its contract, strike and premium.Unlock in Gekko

Revvity earnings: next date and track record

Revvity reports on Feb 1, 2027, before the open (78 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±5%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

+4.1%Nov ’24−2.5%Jan ’25+0.4%Apr ’25−8.9%Jul ’25−2.5%Oct ’25−7.0%Feb ’26+14.5%May ’26−0.2%Aug ’26

Last earnings call, Aug 4, 2026 AI summary

What they said
Revvity reported Q2 2026 pro forma organic growth of 3%, with total revenue above guidance high end and adjusted EPS of $1.41 significantly beating expectations due to operating performance, tax timing, and tariff refunds. Pharma/biotech end markets showed third consecutive quarter of improvement. AI-driven demand boosted high-content screening instruments including the Opera Phenix OptIQ with double-digit growth. Company signed definitive agreement to divest China immunodiagnostics business.
Guidance
Management raised full-year pro forma guidance for organic growth, adjusted operating margin, and adjusted EPS based on stronger Q2 performance and improved second-half optimism. Higher-than-normal instrument backlog exiting Q2 provides favorable positioning for H2.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 4, 2026$1.41
est $1.21
+16.5%$711.0M
est $703.0M
+1.1%−0.2%
May 5, 2026$1.06
est $1.02
+3.9%$711.1M
est $704.1M
+1.0%+14.5%
Feb 2, 2026$1.70
est $1.57
+8.3%$772.1M
est $764.9M
+0.9%−7.0%
Oct 27, 2025$1.18
est $1.14
+3.5%$698.9M
est $699.4M
−0.1%−2.5%
Jul 28, 2025$1.18
est $1.14
+3.5%$720.3M
est $699.9M
+2.9%−8.9%
Apr 28, 2025$1.01
est $0.96
+5.2%$664.8M
est $710.8M
−6.5%+0.4%
Jan 31, 2025$1.42
est $1.38
+2.9%$729.4M
est $665.3M
+9.6%−2.5%
Nov 4, 2024$1.28
est $1.13
+13.3%$684.0M
est $679.7M
+0.6%+4.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Revvity stock forecast and analyst price targets

Analysts’ average 12-month price target for Revvity is $171.07, +10.8% from the last close, from 14 firms rating the stock in the last 90 days.

$171.07consensus 12-month target, +10.8% from the last close
Low $140High $190
Buy6
Hold8
Sell0

Each firm’s latest rating in the last 90 days: 14 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12BernsteinHold, maintained$160+3.6%
Nov 5Leerink PartnersBuy, maintained$180+16.6%
Nov 4Stifel NicolausHold, reiterated$177+14.6%
Nov 4J.P. MorganHold, maintained$160+3.6%
Nov 4Robert W. BairdBuy, maintained$190+23.1%
+2.0%average 20-day move after past Neutral readings
+3.8%average move over the next 20 trading days in the last 5 years
±5.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Revvity seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Revvity averaged +3.8% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−0.6%2021+3.4%2022+12.3%2023−0.1%2024+6.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.1%2 of 5
Next 10 trading days+0.4%2 of 5
Next 15 trading days+0.8%3 of 5
Next 20 trading days+3.8%3 of 5
Next 30 trading days+5.8%3 of 5

For scale, RVTY’s typical 20-trading-day move in either direction is about 5.8%.

Revvity market cap and key statistics

Revvity’s market cap is $17.24B, with a P/E ratio of 70.4 and revenue of $2.94B over the last twelve months.

Valuation

Market cap
$17.24B
P/E ratio
70.4
Forward P/E
26.4
EPS, TTM
$2.23
Gekko Fair Value
$141.76

Trading

Volume
1.31M
Avg volume, 20 days
1.84M
52-week high
$171.74
52-week low
$81.22
Shares outstanding
111.6M

Financials

Revenue, TTM
$2.94B
Profit margin
8.6%
Return on equity
3.5%
Quarterly earnings growth, YoY
+37.8%

Risk and income

Beta
1.09
Typical daily move
±5.6%
Typical 20-day move
±5.8%
Dividend yield
0.18%

Revvity peers

Revvity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Revvity stock FAQ

What is Revvity’s market cap?

Revvity’s market cap is $17.24B at the Nov 13, 2026 close of $154.39, with 111.6M shares outstanding. The shares trade on a P/E ratio of 70.4.

What is the Revvity stock forecast?

The consensus analyst 12-month price target for Revvity is $171.07, +10.8% from the last close. Of the 14 firms that rated the stock in the last 90 days, 6 rate it a buy, 8 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Revvity stock overvalued or undervalued?

On Gekko’s estimate Revvity is overvalued: the Nov 13, 2026 close of $154.39 is 8.9% above Gekko Fair Value of $141.76. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Revvity report earnings next?

Revvity is expected to report on Feb 1, 2027, before the market opens (78 days away). Analysts expect earnings of $1.61 per share on revenue of $759.1M. Revvity beat the earnings estimate in 8 of its last 8 reports, moving 5% on average across the report.

What is Revvity’s 52-week high and low?

Revvity’s 52-week high is $171.74 and its 52-week low is $81.22; it closed at $154.39 on Nov 13, 2026, +64.0% over the past year. Over the last five years the shares peaked at $203.16 on Dec 31, 2021.

Is Revvity stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Revvity?

Gekko flagged 1 unusual options signal in Revvity over the last 30 days, with $271K of flagged premium in calls and $95K in puts. The latest, bullish flow, was on Nov 11, 2026 with $366K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Revvity the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.